Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company developing investigational cancer therapies. Through these filings, investors can review the company’s official disclosures on financial performance, governance, risk factors and progress of its pipeline programs, including the CD47 inhibitor evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe ALX Oncology’s research and development activities, clinical trial portfolio, expenses related to programs such as evorpacept and ALX2004, and other information relevant to its status as a clinical-stage biotechnology company. These reports also discuss risks associated with drug development, regulatory approval and financing.
Current reports on Form 8-K are used by ALX Oncology to disclose material events. For example, the company has filed 8-Ks to furnish quarterly financial results and to announce changes in its board of directors and committee composition. Such filings may incorporate press releases as exhibits and provide timely updates on corporate developments.
Investors interested in insider transactions can review Forms 3, 4 and 5, which report holdings and changes in ownership by directors, officers and certain shareholders. Proxy statements on Schedule 14A offer additional insight into governance matters and executive compensation.
On Stock Titan, ALX Oncology’s SEC filings are updated as they become available from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key sections and clarify technical language, making it easier to understand complex topics such as clinical trial disclosures, R&D spending and risk factor discussions related to the company’s oncology pipeline.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on cancer immunotherapies targeting the CD47 pathway and EGFR. It highlights evorpacept, a CD47 blocker with an inactive Fc domain designed to avoid blood toxicities seen in earlier CD47 drugs, and ALX2004, a novel EGFR-targeted antibody-drug conjugate.
Evorpacept has been studied in gastric, breast, lymphoma and multiple myeloma settings, often combined with antibodies such as trastuzumab, rituximab and zanidatamab. In gastric/GEJ cancer, adding evorpacept to standard HER2-directed therapy improved objective response rates and response duration, especially in tumors with high CD47 expression.
ALX2004, built with an in-house topoisomerase I payload and a matuzumab-derived antibody, showed strong preclinical tumor killing and bystander effect with encouraging non-human primate safety, and is now in a Phase 1 trial in EGFR-expressing solid tumors. As of June 30, 2025, non-affiliate common equity market value was $18.0 million, and 131,608,278 common shares were outstanding as of March 2, 2026.
ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options representing 700,000 shares of the company’s stock. This is recorded as a derivative security transaction categorized as a grant, award, or other acquisition.
According to the vesting terms, one-fourth of the shares subject to the option vest on February 25, 2027, and the remaining portion vests in equal monthly installments of 1/48th thereafter. Following this grant, she is shown as holding 700,000 stock options directly.
ALX Oncology Holdings Inc Chief Medical Officer Barbara Klencke filed an initial Form 3 reporting her equity interests in the company. She lists several stock option awards and common stock positions, reflecting both direct and indirect ownership.
The filing reports stock options over 40,400, 300,000 and 100,000 shares, plus 60,000 common shares held directly and another 60,000 common shares held indirectly by her spouse. Footnotes describe vesting schedules for the options, with installments beginning on February 21, 2025, September 17, 2025, January 31, 2026, June 30, 2026 and February 26, 2026.
ALX Oncology reported 2025 results showing lower expenses and a stronger balance sheet while advancing two key cancer programs. Research and development spending fell to
GAAP net loss narrowed to
Management expects this cash to fund operations through the first half of 2028, covering major milestones for lead CD47 inhibitor evorpacept and EGFR-targeted ADC ALX2004. Multiple clinical data readouts are planned between
ALX Oncology Holdings Inc. senior vice president and chief accounting officer Shelly Pinto reported an open-market sale of 565 shares of common stock at $2.27 per share. According to the disclosure, the shares were sold solely to cover tax obligations from vesting restricted stock units. After this transaction, Pinto holds 87,708 shares directly.
ALX Oncology Holdings CEO Jason Lettmann reported a routine tax-related share withholding. On the RSU vesting date, 2,201 shares of common stock were withheld at $2.27 per share to cover his tax liability, a non‑market disposition. Following this, he directly owns 305,920 shares, which include 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
RA Capital Management and affiliated investors report a significant passive stake in ALX Oncology Holdings Inc. They beneficially own 13,117,106 shares of common stock, representing 9.99% of the company’s outstanding shares, calculated under a 9.99% beneficial ownership blocker.
The Fund directly holds 13,011,849 common shares and pre-funded warrants exercisable for up to 12,473,803 additional shares, but the warrants cannot be exercised if ownership would exceed 9.99%. Voting and investment power over the reported securities is delegated to RA Capital, with certain entities and individuals disclaiming beneficial ownership for purposes other than Section 13(d) reporting.
ALX Oncology Holdings Inc. (ALXO) received a Schedule 13G disclosing a significant passive ownership stake by TCG Crossover funds and Chen Yu. The filing reports that TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their Delaware general partners, each beneficially own 6,505,925 and 6,505,924 shares of Common Stock, respectively, representing 5.0% of the class for each fund.
Chen Yu, as sole managing member of both general partners, is reported to beneficially own 13,011,849 shares of Common Stock, or 9.9% of the outstanding shares, based on 131,197,113 shares of Common Stock. The filing explains that additional shares underlying Pre-Funded Warrants, totaling 3,050,159 for TCG Crossover II and 3,050,158 for TCG Crossover III, are excluded because a 9.99% Beneficial Ownership Limitation prevents exercise within 60 days. The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of ALX Oncology.
venBio Global Strategic Fund II L.P. purchased 3,184,713 shares of ALX Oncology common stock at $1.57 per share in a registered underwritten follow-on offering that closed on February 2, 2026, for an aggregate of approximately $5,000,000, and this amendment updates their Schedule 13D holdings.
Following the transaction, venBio-affiliated funds report beneficial ownership of 4,431,600 shares (3.4%) and 8,453,038 shares (6.4%). Robert J. Adelman reports beneficial ownership of 12,984,044 shares (9.9%), and Corey S. Goodman reports 13,163,549 shares (10%), including 111,541 shares underlying stock options exercisable within 60 days and shares held through a trust and Emaldi Corporation.
The ownership percentages are based on 54,218,001 shares outstanding as of October 31, 2025, plus 76,979,112 shares issued in the February 2026 offering and, for Mr. Goodman, 111,541 option shares. On January 20, 2026, Mr. Goodman was also awarded 40,400 stock options vesting in 12 monthly installments beginning February 20, 2026.
ALX Oncology director and 10% owner Corey S. Goodman, through entities associated with venBio, reported a large indirect purchase of the company’s common stock. On February 2, 2026, venBio Global Strategic Fund II, L.P. acquired 3,184,713 ALX Oncology shares at $1.57 per share, bringing its indirectly reported holdings to 8,453,038 shares. Additional indirect holdings reported for entities linked to Goodman include 3,969,789 shares held by venBio Global Strategic Fund, L.P., 461,811 shares held by venBio SPV, LLC, 113,287 shares held by the Goodman Barinaga Trust, and 54,083 shares held by Emaldi Corporation. Goodman serves in oversight roles at these entities and disclaims beneficial ownership of the securities, except to the extent of his indirect pecuniary interest.